Trial · NCT03057951
Adverse events2,154
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,154
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo | 164 | 2,989 | |
| other | Anaemia | Blood and lymphatic system disorders | 10 mg Empagliflozin | 119 | 2,996 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo | 156 | 2,989 | |
| other | Atrial fibrillation | Cardiac disorders | 10 mg Empagliflozin | 137 | 2,996 | |
| other | Urinary tract infection | Infections and infestations | Placebo | 160 | 2,989 | |
| other | Urinary tract infection | Infections and infestations | 10 mg Empagliflozin | 207 | 2,996 | |
| other | Fall | Injury, poisoning and procedural complications | Placebo | 193 | 2,989 | |
| other | Fall | Injury, poisoning and procedural complications | 10 mg Empagliflozin | 189 | 2,996 | |
| other | Diabetes mellitus | Metabolism and nutrition disorders | Placebo | 200 | 2,989 | |
| other | Diabetes mellitus | Metabolism and nutrition disorders | 10 mg Empagliflozin | 139 | 2,996 | |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Placebo | 194 | 2,989 | |
| other | Hyperkalaemia | Metabolism and nutrition disorders | 10 mg Empagliflozin | 170 | 2,996 | |
| other | Hyperuricaemia | Metabolism and nutrition disorders | Placebo | 208 | 2,989 | |
| other | Hyperuricaemia | Metabolism and nutrition disorders | 10 mg Empagliflozin | 131 | 2,996 | |
| other | Renal impairment | Renal and urinary disorders | Placebo | 181 | 2,989 | |
| other | Renal impairment | Renal and urinary disorders | 10 mg Empagliflozin | 177 | 2,996 | |
| other | Hypertension | Vascular disorders | Placebo | 248 | 2,989 | |
| other | Hypertension | Vascular disorders | 10 mg Empagliflozin | 212 | 2,996 | |
| other | Hypotension | Vascular disorders | Placebo | 176 | 2,989 | |
| other | Hypotension | Vascular disorders | 10 mg Empagliflozin | 212 | 2,996 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03057951/events